tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

KROS Stock Latest News

Strategic Focus on KER-065 and Leadership Changes Justify Buy Rating for Keros Therapeutics
RatingsStrategic Focus on KER-065 and Leadership Changes Justify Buy Rating for Keros Therapeutics
3h ago
KROS
Keros Therapeutics’ Workforce Cuts: Potential Savings vs. Strategic Risks
PremiumCompany Announcements
Keros Therapeutics’ Workforce Cuts: Potential Savings vs. Strategic Risks
7h ago
KROS
Keros Therapeutics: Hold Rating Amid Strategic Focus on KER-065 and Pipeline Adjustments
PremiumRatings
Keros Therapeutics: Hold Rating Amid Strategic Focus on KER-065 and Pipeline Adjustments
21h ago
KROS
Keros Therapeutics to discontinue cibotercept, announces COO departure
PremiumThe Fly
Keros Therapeutics to discontinue cibotercept, announces COO departure
1d ago
KROS
Keros Therapeutics: Hold Rating Amid Strategic Focus on KER-065 and Prudent Resource Allocation
PremiumRatings
Keros Therapeutics: Hold Rating Amid Strategic Focus on KER-065 and Prudent Resource Allocation
1d ago
KROS
Keros Therapeutics: Strategic Shift and Organizational Changes Prompt Hold Rating
PremiumRatingsKeros Therapeutics: Strategic Shift and Organizational Changes Prompt Hold Rating
2d ago
KROS
Keros Therapeutics Announces Strategic Realignment and Leadership Changes
Premium
Company Announcements
Keros Therapeutics Announces Strategic Realignment and Leadership Changes
2d ago
8K
KROS
Keros Therapeutics reports Q2 EPS (76c), consensus ($1.13)
Premium
The Fly
Keros Therapeutics reports Q2 EPS (76c), consensus ($1.13)
2d ago
KROS
Keros Therapeutics Begins Phase 3 Trial for Elritercept
PremiumCompany Announcements
Keros Therapeutics Begins Phase 3 Trial for Elritercept
22d ago
8K
KROS
Keros Therapeutics announces first patient dosed in Phase 3 RENEW trial
PremiumThe Fly
Keros Therapeutics announces first patient dosed in Phase 3 RENEW trial
22d ago
TAK
KROS
Keros Therapeutics Announces CMO Resignation
PremiumCompany Announcements
Keros Therapeutics Announces CMO Resignation
24d ago
8K
KROS
McDonald’s downgraded on GLP-1 drug worries: Wall Street’s top analyst calls
PremiumThe Fly
McDonald’s downgraded on GLP-1 drug worries: Wall Street’s top analyst calls
2M ago
DT
AUB
Keros Therapeutics: Strategic Initiatives and Capital Return Signal Potential Upside
PremiumRatingsKeros Therapeutics: Strategic Initiatives and Capital Return Signal Potential Upside
2M ago
KROS
Keros Therapeutics downgraded to Neutral from Buy at BofA
Premium
The Fly
Keros Therapeutics downgraded to Neutral from Buy at BofA
2M ago
KROS
ADAR1 says Keros needs ‘fresh perspectives in the boardroom’
Premium
The Fly
ADAR1 says Keros needs ‘fresh perspectives in the boardroom’
2M ago
KROS
Keros Therapeutics Concludes Strategic Alternatives Review
PremiumCompany Announcements
Keros Therapeutics Concludes Strategic Alternatives Review
2M ago
8K
KROS
Keros Therapeutics to return $375M in excess capital to stockholders
PremiumThe Fly
Keros Therapeutics to return $375M in excess capital to stockholders
2M ago
KROS
Keros Therapeutics CEO to Speak at Healthcare Conference
PremiumCompany Announcements
Keros Therapeutics CEO to Speak at Healthcare Conference
2M ago
8K
KROS
Hold Rating on Keros Therapeutics Amid Strategic Review and Clinical Setbacks
PremiumRatings
Hold Rating on Keros Therapeutics Amid Strategic Review and Clinical Setbacks
2M ago
KROS
BofA says Keros cost reduction ‘disappoints,’ still sees reasons to like story
PremiumThe FlyBofA says Keros cost reduction ‘disappoints,’ still sees reasons to like story
2M ago
KROS
Keros Therapeutics Announces Major Workforce Reduction Plan
Premium
Company Announcements
Keros Therapeutics Announces Major Workforce Reduction Plan
2M ago
8K
KROS
Keros Therapeutics discontinues development of cibotercept in PAH
Premium
The Fly
Keros Therapeutics discontinues development of cibotercept in PAH
2M ago
KROS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >